Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Power estimation for non-standardized multisite studies.
Benign multiple sclerosis: a distinct clinical entity with therapeutic implications.
The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients.
Interplay between exercise and dietary fat modulates myelinogenesis in the central nervous system.
Gene expression analysis reveals functional pathways of glatiramer acetate activation.
Once-daily AUBAGIO® delayed onset of clinically definite multiple sclerosis (MS) in TOPIC study
Reversible pulmonary artery hypertension in association with interferon-beta therapy for multiple sclerosis.
Treatment of multiple sclerosis with the pregnancy hormone estriol.
Dilantin
Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis.
KIR2DL2 inhibitory pathway enhances Th17 cytokine secretion by NK cells in response to herpesvirus infection in multiple sclerosis patients.
FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.
PHENYTEK®* Capsules (extended phenytoin sodium capsules, USP)
A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
US and EU regulatory authorities accept PLEGRIDY™ (peginterferon beta-1a) marketing applications for review
Antioxidant properties of the triaminopyridine, flupirtine.
Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis.
IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci.
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
Interferon in relapsing-remitting multiple sclerosis.
Extension CombiRx data show no benefit of combined MS drugs
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

Pages